Adrenocortical carcinoma risk factors: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(15 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Adrenocortical carcinoma}}
{{Adrenocortical carcinoma}}
[[CMG]] {{AE}} {{AAM}}
{{CMG}}; {{AE}} {{AAM}} {{MAD}}
==Overview==
==Overview==
==Common Risk Factors==
The most important risk factors for developing adrenocortical cancer are [[Lynch syndrome]][[Beckwith-Wiedemann syndrome|, Beckwith-Wiedemann syndrome,]] [[Carney complex|Carney complex,]] [[Neurofibromatosis type I|Neurofibromatosis type 1,]] [[Multiple endocrine neoplasia type 1]] ([[MEN1]]), and [[Carney complex]].
  Families with [[Li-Fraumeni syndrome]] have increased risk.
==Risk Factors==
Risk factors associated with adrenocortical carcinoma are:
* [[Lynch syndrome]]<ref name="pmid26309352">{{cite journal| author=Carethers JM, Stoffel EM| title=Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer. | journal=World J Gastroenterol | year= 2015 | volume= 21 | issue= 31 | pages= 9253-61 | pmid=26309352 | doi=10.3748/wjg.v21.i31.9253 | pmc=4541378 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26309352 }}</ref>
*[[Beckwith-Wiedemann syndrome]] ([[Beckwith-Wiedemann syndrome|BWS]])<ref name=":0" />
*[[Carney complex]]<ref name="pmid26130139">{{cite journal| author=Correa R, Salpea P, Stratakis CA| title=Carney complex: an update. | journal=Eur J Endocrinol | year= 2015 | volume= 173 | issue= 4 | pages= M85-97 | pmid=26130139 | doi=10.1530/EJE-15-0209 | pmc=4553126 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26130139  }}</ref>
*[[Neurofibromatosis type I|Neurofibromatosis type 1]] <ref name="pmid250305152" />
*[[Multiple endocrine neoplasia type 1]]([[MEN1]])<ref name=":1" />
{| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px" align="center"
 
|+
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Gene mutations}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Clinical picture}}
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Lynch syndrome]]<ref name="pmid26309352" />
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[MSH2]], [[MSH6]], [[MLH1]], [[PMS2]]
|
* [[Colorectal cancer]]
* [[Endometrial cancer]]
* [[Sebaceous gland carcinoma|Sebaceous neoplasms]]
* [[Ovarian cancer]]
* [[Pancreatic cancer]]
* [[Brain cancer]]
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Neurofibromatosis type I|Neurofibromatosis type 1]] <ref name="pmid250305152">{{cite journal| author=Hirbe AC, Gutmann DH| title=Neurofibromatosis type 1: a multidisciplinary approach to care. | journal=Lancet Neurol | year= 2014 | volume= 13 | issue= 8 | pages= 834-43 | pmid=25030515 | doi=10.1016/S1474-4422(14)70063-8 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25030515  }}</ref>
|
* [[NF1]]
|
* [[Malignant]] [[Peripheral nervous system|peripheral nerve]] [[Nerve sheath|sheet]] [[tumor]]
* [[Pheochromocytoma]]
* [[Café au lait spot|Café au lait spots]]
* [[Neurofibroma]]
* [[Optic nerve glioma|Optic glioma]]
* [[Lisch nodule]]
* Skeletal abnormalities
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Multiple endocrine neoplasia type 1|MEN1]]<ref name=":1">{{Cite journal
 
| author = [[B. Gatta-Cherifi]], [[O. Chabre]], [[A. Murat]], [[P. Niccoli]], [[C. Cardot-Bauters]], [[V. Rohmer]], [[J. Young]], [[B. Delemer]], [[H. Du Boullay]], [[M. F. Verger]], [[J. M. Kuhn]], [[J. L. Sadoul]], [[Ph Ruszniewski]], [[A. Beckers]], [[M. Monsaingeon]], [[E. Baudin]], [[P. Goudet]] & [[A. Tabarin]]
| title = Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database
| journal = [[European journal of endocrinology]]
| volume = 166
| issue = 2
| pages = 269–279
| year = 2012
| month = February
| doi = 10.1530/EJE-11-0679
| pmid = 22084155
}}</ref>               
|
* MENIN
|
* [[Foregut]] [[neuroendocrine tumors]]
* [[Pituitary tumors]]
* [[Parathyroid gland|Parathyroid]] [[hyperplasia]]
* Collagenoma
* [[Angiofibroma]]
* [[Adrenal adenoma]]/[[hyperplasia]]
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[Carney complex]]<ref name="pmid26130139" />
|
* [[PRKAR1A]]
|
* [[Adrenal disease]]
* [[Sertoli cell]] [[tumors]]
* [[Thyroid adenoma]]
* [[Myxoma]]
* [[Somatotrope|Somatotroph]] [[pituitary adenoma]]
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |[[BWS]]<ref name=":0">{{Cite journal
 
| author = [[H. Segers]], [[R. Kersseboom]], [[M. Alders]], [[R. Pieters]], [[A. Wagner]] & [[M. M. van den Heuvel-Eibrink]]
| title = Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients
| journal = [[European journal of cancer (Oxford, England : 1990)]]
| volume = 48
| issue = 17
| pages = 3249–3256
| year = 2012
| month = November
| doi = 10.1016/j.ejca.2012.06.008
| pmid = 22796116
}}</ref>
|
* [[IGF2]], [[CDKN1C]], [[H19 (gene)|H19]]
|
* [[Wilm's tumor|Wilm’s tumor]]
* [[Hepatoblastoma]]
* [[Macrosomia]]
* [[Adrenocortical]] cytomegaly
* [[Adrenal adenoma]]
* [[Adrenal Gland|Adrenal]] [[cyst]]
* [[Hemihypertrophy]]
* [[Macroglossia]]
* [[Omphalocele]]
|}
 
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Disease]]
[[Category:Pathology]]
[[Category:Pathology]]

Latest revision as of 15:39, 17 October 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma risk factors On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma risk factors

CDC on Adrenocortical carcinoma risk factors

Adrenocortical carcinoma risk factors in the news

Blogs on Adrenocortical carcinoma risk factors

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

The most important risk factors for developing adrenocortical cancer are Lynch syndrome, Beckwith-Wiedemann syndrome, Carney complex, Neurofibromatosis type 1, Multiple endocrine neoplasia type 1 (MEN1), and Carney complex.

Risk Factors

Risk factors associated with adrenocortical carcinoma are:

Differential Diagnosis Gene mutations Clinical picture
Lynch syndrome[1]
Neurofibromatosis type 1 [4]
MEN1[5]
  • MENIN
Carney complex[3]
BWS[2]

References

  1. ↑ 1.0 1.1 Carethers JM, Stoffel EM (2015). "Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer". World J Gastroenterol. 21 (31): 9253–61. doi:10.3748/wjg.v21.i31.9253. PMC 4541378. PMID 26309352.
  2. ↑ 2.0 2.1 H. Segers, R. Kersseboom, M. Alders, R. Pieters, A. Wagner & M. M. van den Heuvel-Eibrink (2012). "Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients". European journal of cancer (Oxford, England : 1990). 48 (17): 3249–3256. doi:10.1016/j.ejca.2012.06.008. PMID 22796116. Unknown parameter |month= ignored (help)
  3. ↑ 3.0 3.1 Correa R, Salpea P, Stratakis CA (2015). "Carney complex: an update". Eur J Endocrinol. 173 (4): M85–97. doi:10.1530/EJE-15-0209. PMC 4553126. PMID 26130139.
  4. ↑ 4.0 4.1 Hirbe AC, Gutmann DH (2014). "Neurofibromatosis type 1: a multidisciplinary approach to care". Lancet Neurol. 13 (8): 834–43. doi:10.1016/S1474-4422(14)70063-8. PMID 25030515.
  5. ↑ 5.0 5.1 B. Gatta-Cherifi, O. Chabre, A. Murat, P. Niccoli, C. Cardot-Bauters, V. Rohmer, J. Young, B. Delemer, H. Du Boullay, M. F. Verger, J. M. Kuhn, J. L. Sadoul, Ph Ruszniewski, A. Beckers, M. Monsaingeon, E. Baudin, P. Goudet & A. Tabarin (2012). "Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database". European journal of endocrinology. 166 (2): 269–279. doi:10.1530/EJE-11-0679. PMID 22084155. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Adrenocortical_carcinoma_risk_factors&oldid=1375694"